Liz Barrett

News

UroGen appoints former Novartis cancer chief Barrett as CEO

Novartis’ former oncology CEO Liz Barrett has left to join a little known biotech, UroGen, to help bring its potential urothelial cancer drug to market.

Oncology

ASCO 2026: All about DNA damage response, with Luke Piggot

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks